Skip to main content
Evidence Snapshot

Lewis lung carcinoma cell line

CHEMBL614088 CELL-LINE Mus musculus
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:32:54Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614088
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Lewis lung carcinoma cell line as ChEMBL target CHEMBL614088. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Lewis lung carcinoma cell line
CELL-LINE · Mus musculus
As of 2026-09-13
ChEMBL target ID
CHEMBL614088
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Lewis lung carcinoma cell line matters

As of 2026-09-13

Lewis lung carcinoma cell line is reviewed as Lewis lung carcinoma cell line; the current evidence base includes 7 approved drugs, 738 compounds, and 420 assays, with lead potency reaching pChEMBL 9.5.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 7 approved drugs, 738 compounds, and 420 assays for this target. The dominant activity type is IC50. CHEMBL283677 is the current potency anchor at pChEMBL 9.5.

Use CHEMBL283677 as the tractability anchor when discussing potency (pChEMBL 9.5).

Activity source · ChEMBL 36 via Core Engine
7 approved pChEMBL 9.5
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Lewis lung carcinoma cell line matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

738
Total Compounds
420
Total Assays
7
Approved Drugs
IC50: 334.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL283677
 9.5 IC50 —
No preferred name
CHEMBL30628
 9.5 IC50 —
No preferred name
CHEMBL286429
 9.3 IC50 —
No preferred name
CHEMBL285349
 8.9 IC50 —
No preferred name
CHEMBL80217
 8.8 IC50 —

Approved Drugs

Structure Compound First Approval
PACLITAXEL
CHEMBL428647
 1992
AMSACRINE
CHEMBL43
 1987
ETOPOSIDE
CHEMBL44657
 1983
DAUNORUBICIN
CHEMBL178
 1979
DOXORUBICIN
CHEMBL53463
 1974
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:32:54Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL614088